Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 1;16(4):484.
doi: 10.3390/pharmaceutics16040484.

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions

Lixuan Qian  1 , Jessica L Beers  2 , Klarissa D Jackson  2 , Zhu Zhou  1
Affiliations
Review

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions

Lixuan Qian et al. Pharmaceutics. .

Abstract

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug-drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC-drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

Keywords: cannabidiol; delta-9-tetrahydrocannabinol; drug–drug interaction; special population.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cox E.J., Maharao N., Patilea-Vrana G., Unadkat J.D., Rettie A.E., McCune J.S., Paine M.F. A Marijuana-Drug Interaction Primer: Precipitants, Pharmacology, and Pharmacokinetics. Pharmacol. Ther. 2019;201:25–38. doi: 10.1016/j.pharmthera.2019.05.001. - DOI - PMC - PubMed
    1. Lafaye G., Karila L., Blecha L., Benyamina A. Cannabis, Cannabinoids, and Health. Dialogues Clin. Neurosci. 2017;19:309–316. doi: 10.31887/DCNS.2017.19.3/glafaye. - DOI - PMC - PubMed
    1. Zhou Z., Paine M.F., Spindle T.R., Huang S., Zhang L. Cannabis for Medical Use: Clinical Pharmacology Perspectives on Scientific and Regulatory Challenges. Clin. Pharmacol. Ther. 2022;111:732–735. doi: 10.1002/cpt.2470. - DOI - PMC - PubMed
    1. Lucas C.J., Galettis P., Schneider J. The Pharmacokinetics and the Pharmacodynamics of Cannabinoids. Br. J. Clin. Pharmacol. 2018;84:2477–2482. doi: 10.1111/bcp.13710. - DOI - PMC - PubMed
    1. Kesner A.J., Lovinger D.M. Cannabis Use, Abuse, and Withdrawal: Cannabinergic Mechanisms, Clinical, and Preclinical Findings. J. Neurochem. 2021;157:1674–1696. doi: 10.1111/jnc.15369. - DOI - PMC - PubMed

LinkOut - more resources